Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 40Recruiting 26Terminated 16Active not recruiting 14Withdrawn 8Unknown 5Not yet recruiting 2Suspended 1Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Leukemia, Myeloid, Acute 1Breast Neoplasms 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 116Bevacizumab 102Capecitabine 100Oxaliplatin 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 85pembrolizumab 77Specimen Handling 77toripalimab 70Magnetic Resonance Spectroscopy 63Injections 63Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 51fludarabine 47Standard of Care 45Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43venetoclax 42Leucovorin 42lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × talazoparib × Clear all
NCT04982848 2025-11-18

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Pfizer

Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT05319249 2024-04-05

NAKIP-AML

German Cancer Research Center

Phase 1/2 Not yet recruiting
54 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡